389 related articles for article (PubMed ID: 21948478)
1. Next-generation oncolytic vaccinia vectors.
Thorne SH
Methods Mol Biol; 2012; 797():205-15. PubMed ID: 21948478
[TBL] [Abstract][Full Text] [Related]
2. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic vaccinia virus: from bedside to benchtop and back.
Thorne SH
Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
[TBL] [Abstract][Full Text] [Related]
4. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.
Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815
[TBL] [Abstract][Full Text] [Related]
5. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
6. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
7. Design and testing of novel oncolytic vaccinia strains.
Thorne SH
Methods Mol Biol; 2009; 542():635-47. PubMed ID: 19565925
[TBL] [Abstract][Full Text] [Related]
8. Vaccinia virus and oncolytic virotherapy of cancer.
Thorne SH; Hwang TH; Kirn DH
Curr Opin Mol Ther; 2005 Aug; 7(4):359-65. PubMed ID: 16121702
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus.
Deng H; Tang N; Stief AE; Mehta N; Baig E; Head R; Sleep G; Yang XZ; McKerlie C; Trudel S; Stewart AK; McCart JA
Leukemia; 2008 Dec; 22(12):2261-4. PubMed ID: 18509356
[No Abstract] [Full Text] [Related]
10. [Oncolytic poxviruses].
Kochneva GV; Sivolobova GF; Iudina KV; Babkin IV; Chumakov PM; Netesov SV
Mol Gen Mikrobiol Virusol; 2012; (1):8-15. PubMed ID: 22702138
[TBL] [Abstract][Full Text] [Related]
11. United virus: the oncolytic tag-team against cancer!
Le Boeuf F; Bell JC
Cytokine Growth Factor Rev; 2010; 21(2-3):205-11. PubMed ID: 20227326
[TBL] [Abstract][Full Text] [Related]
12. Vaccinia virus GLV-1h237 carrying a Walker A motif mutation of mouse Cdc6 protein enhances human breast tumor therapy in mouse xenografts.
Hofmann E; Grummt F; Szalay AA
Int J Oncol; 2011 Mar; 38(3):871-8. PubMed ID: 21249314
[TBL] [Abstract][Full Text] [Related]
13. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
[TBL] [Abstract][Full Text] [Related]
14. Preclinical testing of virotherapeutics for primary and secondary tumors of the liver.
Zimmermann M; Weiland T; Bitzer M; Lauer UM
Methods Mol Biol; 2012; 806():121-36. PubMed ID: 22057449
[TBL] [Abstract][Full Text] [Related]
15. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent.
Gentschev I; Stritzker J; Hofmann E; Weibel S; Yu YA; Chen N; Zhang Q; Bullerdiek J; Nolte I; Szalay AA
Cancer Gene Ther; 2009 Apr; 16(4):320-8. PubMed ID: 18949014
[TBL] [Abstract][Full Text] [Related]
16. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.
Guo ZS; Naik A; O'Malley ME; Popovic P; Demarco R; Hu Y; Yin X; Yang S; Zeh HJ; Moss B; Lotze MT; Bartlett DL
Cancer Res; 2005 Nov; 65(21):9991-8. PubMed ID: 16267024
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic HSV as a vector in cancer immunotherapy.
Li H; Zhang X
Methods Mol Biol; 2010; 651():279-90. PubMed ID: 20686972
[TBL] [Abstract][Full Text] [Related]
18. Virus combinations and chemotherapy for the treatment of human cancers.
Kumar S; Gao L; Yeagy B; Reid T
Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
[TBL] [Abstract][Full Text] [Related]
19. Enhancing poxvirus oncolytic effects through increased spread and immune evasion.
Kirn DH; Wang Y; Liang W; Contag CH; Thorne SH
Cancer Res; 2008 Apr; 68(7):2071-5. PubMed ID: 18381410
[TBL] [Abstract][Full Text] [Related]
20. Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies.
Kinoh H; Inoue M; Komaru A; Ueda Y; Hasegawa M; Yonemitsu Y
Gene Ther; 2009 Mar; 16(3):392-403. PubMed ID: 19037241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]